The multidrug resistance 1 (MDR1) gene transfer to hematopoietic cells for protection against cytotoxic drugs has received considerable attention in gene therapy. However, ectopic expression of MDR1 from retroviral vectors has been hampered by its genetic instability resulting from cryptic splice sites within the cDNA. We have evaluated the efficiency of retroviral MDR1 vectors with introduced mutations of the MDR1 cryptic splice donor (cSD) located at nucleotide +339 and of the cryptic splice acceptor (cSA) at nucleotide +2319 of the cDNA. Sequence alterations of the cSD reduced the expression of MDR1 P-glycoprotein (P-gp), even when generated as silent mutations. A silent mutation of the cSA reduced the splicing activity shifting the splice acceptor site one base downstream; however, it significantly improved the expression of P-gp. The incidence of wild-type MDR1 pregenome splicing was markedly reduced when vectors were produced in human 293 packaging cells as opposed to murine PG13 and GP+envAm12. We conclude that complete splice correction of MDR1 in retroviral vectors may only be achieved with extensive alterations of the cDNA or neighboring vector sequences and that the splicing is significantly influenced by the choice of the packaging cells.
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The human multidrug resistance 1 (MDR1) gene encodes P-glycoprotein (P-gp), a member of the ABC transporter superfamily. P-gp is localized in the cell membrane and mediates ATP-dependent efflux of xenobiotics out of cells. MDR1 has been widely used in human gene therapy research to prevent side effects of cytotoxic cancer drugs in healthy tissues, and as a selection marker for genetically modified hematopoietic cells. 1, 2 The latter application requires the use of retroviral vectors, as these currently represent the only tool approved for clinical use that mediates stable transgene insertions at defined copy numbers in the genome of target cells. However, retroviral expression of MDR1 is hampered by genetic instability resulting from cryptic splice sites within the cDNA. 3 A cryptic MDR1 splice donor (cSD) has been located at +339 of the cDNA. This tends to interact with a cryptic splice acceptor (cSA) found at +2319, giving rise to alternative splicing in about 50% of transcripts. If this occurs, as so-called pregenome splicing in packaging cells used for vector production, vector particles with defective transgenes containing a deletion within the cDNA are generated. Even when target cells are transduced with a correct version of the retroviral transgene, internal splicing of the MDR1 cDNA may still reduce the expression of the encoded protein.
Another concern is that the 'aberrant' splice product may encode protein variants that have an immunogenic or toxic potential.
Silent mutations introduced into both sites were reported to generate a 'splice-corrected' version of MDR1. Using bicistronic retroviral vectors, intact length of the MDR1 cDNA in transduced cells without previous selection for MDR1 activity was achieved. 4 However, the use of retroviral MDR1 vectors encoding the 'splicecorrected' cDNA from a backbone derived from the Harvey murine sarcoma virus (HaMSV) was complicated by the occurrence of myeloproliferative disorders in mice transplanted with gene-modified hematopoietic cells, 5, 6 while these disorders were not observed with vectors containing the wild-type cDNA. 2, 7, 8 The myeloproliferative disease was associated with a high copy number of retroviral MDR1 transgenes in transformed cells, 6 while it was not seen in monkeys transduced with a low copy number of the vector. 9 Clinical trials, conducted with vectors encoding 'uncorrected' MDR1, showed no evidence for vector-related toxicity; however, they were hampered by an incomplete expression of the multidrug-resistant phenotype.
This study addresses how mutations of cSD and cSA affect the stability and expression of retroviral MDR1 vectors. We have chosen vectors containing the enhancer-promoter of spleen focus forming virus (SFFVp), to ensure sufficient expression in hematopoietic cells from single vector insertions. [16] [17] [18] In order to analyze a potential impact of splice sites located in the 5 0 untranslated regions (5 0 UTR) of retroviral vectors, different leader regions have been tested. All contained the retroviral splice donor (rSD) 5 0 of the packaging sequence (C), a configuration required for high titer packaging, 17 with either no (pSF11, GenBank Accession AJ132035), a strong (pSF91, AJ132037) or a weak (pSF1, AJ224005) retroviral splice acceptor (rSA) downstream of C and 5 0 of MDR1. The cSD was altered by a silent point mutation (RR-SD), a point mutation generating a conservative aminoacid exchange of arginine to lysine (RK-SD) or a codon deletion (DSD); mutations of the cSA were also either silent, as described earlier (QQ-SA), 4 conservativeglutamine to asparagine (QN-SA), or a complete codon deletion (DSA) ( Table 1) , all maintaining the downstream reading frame of MDR1. Low multiplicity of infection (MOI) was used in all vector studies. Quantitative realtime PCR analysis of the amount of MDR1 cDNA normalized to erythropoietin receptor (EPOR) DNA as a single copy gene revealed that the efficiency of MDR1 cDNA transfer was similar for all vectors used ( Table 2) . Equal gene dosage limited to one copy per cell in the majority of transduced cells remained stable in the cells resistant to colchicine (5-40 ng/ml), as verified by quantitative real-time PCR analysis of MDR1 cDNA content (data not shown). The only exception was the vector with the QN-SA mutation where a significantly higher proportion of transduced cells was observed ( Table 2) .
Mutations of cSD did not improve the function of the MDR1 vectors. Unexpectedly, RR-SD, the mutation present in the 'splice-corrected' MDR1, 4 reduced MDR1 mRNA and protein expression in K562 target cells. This was shown by quantitative real-time RT-PCR (Table 2) and by using a sensitive assay for MDR1 expression, that is, exposure of transduced but unselected cells to increasing concentrations of colchicine, a cytotoxic agent recognized by the P-gp efflux pump. [16] [17] [18] At high doses of colchicine, RR-SD showed a two-fold (not statistically significant) reduced cloning efficiency compared with 'uncorrected' MDR1. The other two tested cSD mutants were even more attenuated in expression and/or function ( Figure 1a ).
Most cSA mutations were also deleterious. Colchicineresistant colony-forming assay revealed that the QN-SA mutation reduced the function of MDR1, while DSA abolished the phenotype completely. Only the silent QQ-SA mutation significantly improved the vector performance in higher concentrations of colchicine ( Figure 1b ). Using quantitative real-time PCR we proved that the better function of QQ-SA was not because of a higher copy number of integrated MDR1 cDNA (data not shown). The combination of RR-SD and QQ-SA, as present in the 'splice-corrected' MDR1, 4 resulted in weak chemoprotection similar to RR-SD alone, suggesting a dominant effect of RR-SD over QQ-SA. The results The colonies of surviving cells were counted after 12 days of cultivation and expressed as percent of colonies surviving in 5 ng/ml of colchicine (designated as 100%). Means and s.e.m. from 3-6 independent experiments are shown. The difference between the resistance of K562 cells transduced with wt and QQ-SA MDR1 to colchicine 20 and 40 ng/ml was statistically significant (*, t-test, Po0.02). Deletion of one amino acid in cSA (DSA) completely abolished the P-gp function, no surviving colonies were detected at 5 ng/ml colchicine.
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Status of aberrant splicing was investigated by RT-PCR performed with polyA+ RNA isolated from unselected K562 cells transduced with the different vectors ( Figure  2 ). The major MDR1 splice event between cSD +339 and cSA +2319 was abolished by all cSD mutations and by cSA mutations QN-SA and DSA. Surprisingly, QQ-SA, the only mutation improving MDR1 protein expression, did not abolish the internal MDR1 splice event. Sequencing of the RT-PCR product revealed that the cSA was shifted just one base downstream by this mutation (Figure 3a) . Using quantitative real-time RT-PCR, we determined that the frequency of QQ-SA splicing in K562 was slightly lower (0.036) than in wt mRNA (0.052), this fact and a higher expression of QQ-SA MDR1 mRNA (Table 2) could explain a better resistance of QQ-SA K562 in higher concentrations of colchicine (Figure 1b) .
Both spliced versions of MDR1 have 113 common amino acids at the N-terminus of the protein, but different C-termini 3 0 of cSA. The 'uncorrected' splice product encodes 27 new amino acids, the protein from spliced QQ-SA has 30 new amino acids at the C-end of the protein. These new protein parts, encoded from different frame-shifts, showed no homologies to known protein sequences in a database search (Figure 3b) . In addition to the previously described major cryptic splicing, we also observed another aberrant splicing occurring in low frequency in K562 cells expressing all , where -2.5 was the DCT value corresponding to a single vector copy per cell. This value was calculated as the mean DCT(EPOR-MDR1) in K562 cells resistant to colchicine at 5 ng/ml after transduction with different variants of MDR1 vectors (28 experiments, mean=À2.5; s.d.=0.5). Resistance to colchicine expressed as a ratio between colony numbers in cultures with 5 ng/ml of colchicine and colony numbers in cultures without colchicine were measured as described. 16, 20 Unpaired Student's t-test was used to compare splice-site-modified vectors with the wild-type MDR1. *Po0.05. Figure 2 Effect of the site-directed mutagenesis on the MDR1 splicing. K562 in exponential phase of growth were transduced by retroviral particles containing different variants of MDR1 cDNA that were generated by the Pantropic Retroviral Expression System (Clontech, Palo Alto, CA, USA). PolyA+ RNA was isolated from untransduced and transduced K562 cells using RNazol B (MRC, Cincinnati, OH, USA) followed by PolyATtract mRNA Isolation System (Promega, Madison, WI, USA) and reverse transcribed with SuperScriptII reverse transcriptase (Gibco BRL) and oligo(dT) 18 primer, control reaction without reverse transcriptase was run in parallel. cDNAs were amplified with MDRspecific primers surrounding the previously described cryptic splicing sites (MDR-AN-F 5 0 TATGGTGGTGGGAACTTTGG, MDR-AN-R 5 0 CCTGT CTGAGCATGGATCGG). K562: untransduced cells used as a negative control. A major splicing variant was detected in cells transduced with wt MDR1 vector and vector with the silent mutation of cSA (QQ-SA). A new minor splicing variant of MDR1 mRNA was identified in all vectors except DSA and proved by sequencing. The other minority bands were not sequenced.
J Cmejlova et al variants of MDR1 cDNA except DSA where the branching point could be affected (Figure 2) . Sequencing of the RT-PCR product identified new cryptic splice donor (+490) and acceptor (+2360) sites (Figure 3a) .
To further evaluate the impact of silent point mutations on P-gp expression, we used the SF1MIN vectors coexpressing MDR1 and the neomycin resistance gene (neoR) linked by an internal ribosomal entry site. 19 Uncloned transduced cells were selected for G418 resistance mediated by neoR 19 and used for further analysis. Confirming the data of Galipeau et al, 4 RR-SD increased the frequency of MDR1-expressing cells from 50% (uncorrected) to 94% (RR-SD) when analyzed by Rhodamine 123 exclusion assay (data not shown). However, as noted earlier in our colony assays, flow cytometry using anti-human P-gp-specific antibodies revealed that P-gp expression from the silent RR-SD mutant was lower than from the 'uncorrected' gene (data not shown).
In the course of our experiments, we observed that the choice of the packaging cells had a significant impact on the expression of Pgp determined by the Rhodamine 123 exclusion assay and the colchicine-resistant colony assay. For this purpose, we compared three widely used retroviral packaging cell lines: murine GP+envAm12 and PG13, and human GP293 cells from Pantropic Retroviral Expression System (Clontech, Palo Alto, CA, USA). One possibility is the generation of defective particles owing to an aberrant splicing in packaging cell lines. To test the hypothesis of the different splicing level in different cell lines, we used quantitative real-time RT-PCR method for the evaluation of the spliced/unspliced ratios of MDR1 RNA transiently generated in the packaging cell lines after transfection with MDR1 vector plasmids. Human GP293 cells produced a significantly lower proportion of spliced MDR1 transcripts than both murine packaging cell lines (Table 3) . Moreover, in PG13 transfected with RR-SD another cryptic splice donor site within the MDR1 cDNA was recruited upstream (position +100) of the originally described cSD as was Green detection of amplified products was used to detect the major splicing event between the cSD at +339 and cSA at +2319 of the MDR1 cDNA. The difference in threshold amplification cycles Ä CT(UÀS) for the unspliced (U, primers mdr1-2259F 5 0 GTTTTCACTATTGTTTCTAGCCCTTGG and mdr1-2337R 5 0 AGCTTTGCCAAATGTGAAACC) and spliced (S, primers mdr1-314F 5 0 TGAATCTGGAGGAAGACATGACC and mdr1-2337R) cDNA for MDR1 was determined.
b The spliced fraction was calculated from the formula 2 Ä CT(UÀS) /(1+2 Ä CT(UÀS) ). Unpaired Student 0 s t-test was used to compare the respective spliced fractions with the wt MDR1 vector produced in human GP293 packaging cells.*Po0.05.Murine packaging cells GP+envAM12 and PG13 produced a significantly higher amount of spliced wt MDR1 mRNA than human GP293 cells. Alterations of cryptic splice donor and acceptor sites significantly reduced the splicing frequency of vectors produced in all packaging cells tested.
J Cmejlova et al identified by RT-PCR and sequencing (not shown). Thus, the choice of packaging cell line significantly affected the amount of functionally defective recombinant virus particles. In summary, sequence alterations of the cSD reduced MDR1 protein expression from retroviral vectors, even when generated as a silent mutation. As codon usage frequency was not altered by this mutation, structural characteristics of the cDNA-derived MDR1 mRNA may be responsible for this effect. Alternatively, splice factors binding to the cSD may be involved in the nuclear export of RNA, as indicated from studies with the rSD. 17 A silent mutation of the cSA reduced the splicing incompletely, with a one base shift of splice acceptor site, resulting in an increased probability of transferring intact transgene copies to target cells. Although the usage of the CAA codon generated by the silent cSA mutation is three times less frequent than that of the wt CAG codon, the expression of MDR1 protein in target cells was higher. Our results obtained with the cSA indicate that a splicing reaction initiated from a cSD will likely search for alternative cSA sequences within the downstream sequence to complete splicing. These data imply that predictions of 'splice-corrections' may be misleading when relying on sequence data alone. Interestingly, the incidence of MDR1 pregenome splicing was dependent on the cell type expressing the retroviral transcript. Retroviral vectors produced by human packaging cells GP293 were subjected to considerably less MDR1 splicing than vectors produced by murine packaging cells GP+envAm12 or PG13. Thus, complete splice correction of MDR1 in retroviral vectors may only be achieved with extensive alterations of the cDNA or neighboring sequences. The incidence of pregenome splicing of retroviral vectors is also influenced by the type of cells used for vector packaging.
